Regenerative Medicine, Neurology. Company has developed patient-derived, adult stem cell based therapies for the treatment of neurological damage from spinal cord injury, thereby circumventing the use of generic or embryonic stem cells. Through a standard ENT procedure a patients own stem cells are harvested and then matured in a disease-specific manner to obtain a cellular population that serves to induce repair of neural damage when implanted into the site of spinal cord injury. Currently there are 250,000 patients afflicted with spinal cord injury in the US alone, with 13,000 new cases annually, a market that exceeds $20 billion. Further developments of the company’s technology are underway to treat other neurological disorders, including Multiple Sclerosis and Parkinson’s disease. The company currently seeks Series B funding to develop and commercialize its lead product for spinal cord injuries, specifically to submit an IND and commence phase I trials in 2010. Founded: 2005.